<DOC>
	<DOCNO>NCT01650168</DOCNO>
	<brief_summary>This study compare risk short- long-term use NOMAC-E2 ( contain fix dose nomegestrol acetate estradiol ) compare levonorgestrel-containing combined oral contraceptive ( COC-LNG ) study population representative actual user individual preparation .</brief_summary>
	<brief_title>Prospective Controlled Cohort Study Safety Monophasic Oral Contraceptive Containing Nomegestrol Acetate ( 2.5mg ) 17ß-estradiol ( 1.5mg )</brief_title>
	<detailed_description>NOMAC-E2 novel monophasic oral contraceptive contain fix dose nomegestrol acetate ( 2.5mg ) 17ß-estradiol ( 1.5mg ) take 24 day follow 4 day placebo . The relevant adverse clinical outcome link use COCs venous thromboembolism ( VTE ) . Data randomize clinical trial show serious health concern NOMAC-E2 . However , statistical power detect rare adverse event limited study . PRO-E2 large , prospective , control , long-term active surveillance study investigate safety NOMAC-E2 regard outcomes interest . This study follow European Active Surveillance ( EURAS ) design methodology modification due country- product-specific characteristic . The outcomes interest validate via attend physician . A multi-faceted follow-up procedure ensure low loss follow-up rate . This study involve woman Europe Australia follow 2 year . Data analysis include multivariable technique Cox regression .</detailed_description>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>First ever user COC ( `` starter '' ) User restart hormonal contraceptive use COC ( COC new COC ) intake break least two month ( `` restarters '' ) Women willing participate active surveillance Women understand major aspect study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NOMAC-E2</keyword>
	<keyword>Nomegestrol acetate</keyword>
	<keyword>Estradiol</keyword>
	<keyword>Levonorgestrel</keyword>
	<keyword>Safety</keyword>
</DOC>